EFFECTIVENESS OF INTERFERON INDUCER IN PATIENTS WITH BRONCHIAL ASTHMA EXACERBATION IN TIME OF RESPIRATORY VIRAL EPIDEMIC

The paper deals with the research on the dynamics of change in IFN status as well as interferon-producing capacity of leucocytes in vitro. 54 bronchial asthma patients with different forms of asthma had been tested before they went through cycloferon treatment, during the treatment, and after it. 16 (30%) of the tested had an allergic form of bronchial asthma, 21 (39%) had a mixed form, аnd 17 (31%) had a non-allergic form. With all the patients, the exacerbation of bronchial asthma was provoked by acute respiratory viral infections. The research showed that initially high IFN-γ (>8 pg/ml, control - 6.8±1.2 pg/ml) index in the patients' blood serum results from persistent viral and, probably, bacterial infections and causes active inflammatory process in bronchial asthma patients. Low initial indices of IFN-γ (<4 pg/ml) in blood serum and decrease in the capacity of blood leucocytes to produce IFN-α and IFN-γ point to the weakening of anti-virus body resistance, which results in the increase of the risk of acute respiratory viral infections and worsening of bronchial asthma. Introduction of cycloferon in the complex treatment of patients with different forms of bronchial asthma leads to the increase in IFN level, contributes to IFN-synthesis capacity of blood leucocytes, causes a decrease in the rates of acute respiratory viral infections and exacerbations of the basic disease.

bronchial asthma, acute respiratory viral infections, leucocytes, interferon, cycloferon

1. Роль респираторных вирусов в развитии аллергии / В.Б.Гервазиева [и др.] // Цитокины и воспаление. 2003. Т.2, №3. С.3-8.

2. Кетлинский С.А. Роль Т-хелперов типов 1 и 2 в регуляции клеточного и гуморального иммунитета // Иммунология. 2002. № 2. С.77-79.

3. Прогностическое значение исследования IL-4, IFN-γ и IgE в конденсате выдыхаемого воздуха при бронхиальной астме и аллергическом рините у детей / Т.Н.Суровенко [и др.] // Цитокины и воспаление. 2002. Т.1, №4. С.38-42.

4. Циклоферон в клинической практике: методические рекомендации для врачей / под ред. В.А.Исакова. СПб: Полисан, 2003. 44 с.

5. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus / R.Arnold [et al.] // Immunology. 1994. Vol.82, №1. P.126-133.

6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (Update 2008). URL: http://www.ginasthma.com (дата обращения: 18.11.2011).

7. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils / Y.Kameyoshi [et al.] // J. Exp. Med. 1992. Vol.176, №2. P.587-592.

8. Adhesion to VCAM-1 and exposure to GM-CSF synergistically activate eosinophil superoxide anion (O2) generation and degranulation / M.Nagata [et al.] // Am. J. Respir. Crit. Care Med. 1995. Vol.151. P.240.

9. Pattemore P.K., Johnston S.L., Bardin P.G. Viruses as precipitants of asthma symptoms. 1. Epidemiology // Clin. Exp. Allergy. 1992. Vol.22, №3. P.325-336.

10. Renauld J.C. New insights into the role of cytokines in asthma // J. Clin. Pathol. 2001. Vol.54, №8. P.577-589.

11. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction / W.Tang [et al.] // J. Clin. Invest. 1996. Vol.98, №12. P.2845-2853.

12. Gervazieva V.B., Sveranovskaya V.V., Shternshis Yu.A., Semenov B.F. Tsitokiny i vospalenie 2003; 2(3):3-8.

13. Ketlinskiy S.A. Immunologiya 2002; 2:77-79.

14. Surovenko T.N., Shelud'ko Ya.S., Ovchinnikova O.V., Markelova E.V., Gel'tser B.I. Tsitokiny i vospalenie 2002; 1(4):38-42.

15. Isakov V.А., editor. Tsikloferon v klinicheskoy praktike: metodicheskie rekomendatsii dlya vrachey [Cycloferone in clinical practice: guidelines for doctors]. St. Petersburg: Polisan; 2003.

16. Arnold R., Humbert B., Werchau H., Gallati H., König W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology 1994; 82(1):126-133.

17. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (Update 2008). Available at: www.ginasthma.com <http://www.ginasthma.com>.

18. Kameyoshi Y., Dörschner A., Mallet A.I., Christophers E., Schröder J.M. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J. Exp. Med. 1992; 176(2):587-592.

19. Nagata M., Sedgwick J.B., Kita H., Busse W.W. Adhesion to VCAM-1 and exposure to GM-CSF synergistically activate eosinophil superoxide anion (O2) generation and degranulation. Am. J. Respir. Crit. Care Med. 1995; 151:А240 (Abstract).

20. Pattemore P.K., Johnston S.L., Bardin P.G. Viruses as precipitants of asthma symptoms. 1. Epidemiology. Clin. Exp. Allergy 1992; 22(3):325-336.

21. Renauld J.C. New insights into the role of cytokines in asthma. J. Clin. Pathol. 2001; 54(8):577-589.

22. Tang W., Geba G.P., Zheng T., Ray P., Homer R.J., Kuhn C. 3rd, Flavell R.A., Elias J.A. Targeted expression of IL-11 in the murine airway causes lymphocytic inflammation, bronchial remodeling, and airways obstruction. J. Clin. Invest. 1996; 98(12):2845-2853.